CA2918233C - Procede pour la preparation d'un element neurotoxique hautement pur d'une toxine botulinique et ses utilisations - Google Patents
Procede pour la preparation d'un element neurotoxique hautement pur d'une toxine botulinique et ses utilisations Download PDFInfo
- Publication number
- CA2918233C CA2918233C CA2918233A CA2918233A CA2918233C CA 2918233 C CA2918233 C CA 2918233C CA 2918233 A CA2918233 A CA 2918233A CA 2918233 A CA2918233 A CA 2918233A CA 2918233 C CA2918233 C CA 2918233C
- Authority
- CA
- Canada
- Prior art keywords
- neurotoxic component
- botulinum toxin
- clostridium botulinum
- highly pure
- isolator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M37/00—Means for sterilizing, maintaining sterile conditions or avoiding chemical or biological contamination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/40—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Sustainable Development (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention porte sur un procédé pour la préparation d'un élément neurotoxique hautement pur d'une toxine botulinique par culture de Clostridium botulinum dans des conditions qui permettent la production d'une toxine botulinique et par isolement de l'élément neurotoxique à partir de la toxine botulinique. De plus, la présente invention porte sur un élément neurotoxique hautement pur d'une toxine botulinique pouvant être obtenu par le procédé selon la présente invention et sur ses utilisations.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13003792.2 | 2013-07-30 | ||
EP13003792 | 2013-07-30 | ||
PCT/EP2014/002089 WO2015014487A1 (fr) | 2013-07-30 | 2014-07-30 | Procédé pour la préparation d'un élément neurotoxique hautement pur d'une toxine botulinique et ses utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2918233A1 CA2918233A1 (fr) | 2015-02-05 |
CA2918233C true CA2918233C (fr) | 2022-08-30 |
Family
ID=48906087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2918233A Active CA2918233C (fr) | 2013-07-30 | 2014-07-30 | Procede pour la preparation d'un element neurotoxique hautement pur d'une toxine botulinique et ses utilisations |
Country Status (13)
Country | Link |
---|---|
US (2) | US9937245B2 (fr) |
EP (1) | EP3027641A1 (fr) |
JP (1) | JP6517800B2 (fr) |
KR (1) | KR102272580B1 (fr) |
CN (1) | CN105658662B (fr) |
AU (1) | AU2014298922B2 (fr) |
BR (1) | BR112016001730B1 (fr) |
CA (1) | CA2918233C (fr) |
HK (1) | HK1225744A1 (fr) |
IL (1) | IL243573B (fr) |
MX (1) | MX2016001220A (fr) |
RU (1) | RU2663136C2 (fr) |
WO (1) | WO2015014487A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10792344B2 (en) * | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
WO2015014487A1 (fr) * | 2013-07-30 | 2015-02-05 | Merz Pharma Gmbh & Co. Kgaa | Procédé pour la préparation d'un élément neurotoxique hautement pur d'une toxine botulinique et ses utilisations |
KR102557798B1 (ko) * | 2014-12-23 | 2023-07-19 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소 사전충전된 용기 |
ES2944139T3 (es) | 2015-03-26 | 2023-06-19 | Vensica Medical Ltd | Administración de fármacos ultrasónica a vejiga urinaria |
CA3095598A1 (fr) | 2018-04-01 | 2019-10-10 | Vensica Medical Ltd. | Systeme et procede d'administration d'agent therapeutique ultrasonore pour vessie |
JP6875318B2 (ja) * | 2018-04-24 | 2021-05-19 | 株式会社日立産機システム | 安全キャビネット |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
RU2206337C1 (ru) * | 2002-10-29 | 2003-06-20 | Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" | Лекарственный препарат для лечения мышечных дистоний и способ его получения |
US7339671B2 (en) * | 2004-01-20 | 2008-03-04 | Hong Peng | Apparatus and method for monitoring biological cell culture |
PL1891200T3 (pl) * | 2005-06-17 | 2009-10-30 | Merz Pharma Gmbh & Co Kgaa | Urządzenie i sposób do fermentacyjnego wytwarzania biologicznie aktywnych materiałów |
NZ568216A (en) * | 2005-11-17 | 2012-09-28 | Revance Therapeutics Inc | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
WO2010022979A1 (fr) * | 2008-08-29 | 2010-03-04 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxines clostridiales avec persistance altérée |
EP2248518B1 (fr) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation pour stabiliser des protéines, des peptides et ses mélanges. |
US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
CA2773396C (fr) * | 2009-10-21 | 2020-12-15 | Revance Therapeutics, Inc. | Procedes et systemes pour putifier la neurotoxine botulique non complexee |
US20120189677A1 (en) * | 2011-01-20 | 2012-07-26 | Stephen Tonge | Formulations |
FR2981386B1 (fr) * | 2011-10-14 | 2014-08-22 | Getinge La Calhene | Mecanisme de commande a haut niveau de securite pour un dispositif de transfert etanche entre deux volumes clos |
WO2015014487A1 (fr) * | 2013-07-30 | 2015-02-05 | Merz Pharma Gmbh & Co. Kgaa | Procédé pour la préparation d'un élément neurotoxique hautement pur d'une toxine botulinique et ses utilisations |
-
2014
- 2014-07-30 WO PCT/EP2014/002089 patent/WO2015014487A1/fr active Application Filing
- 2014-07-30 RU RU2016103329A patent/RU2663136C2/ru active
- 2014-07-30 MX MX2016001220A patent/MX2016001220A/es active IP Right Grant
- 2014-07-30 CA CA2918233A patent/CA2918233C/fr active Active
- 2014-07-30 BR BR112016001730-7A patent/BR112016001730B1/pt active IP Right Grant
- 2014-07-30 JP JP2016530382A patent/JP6517800B2/ja active Active
- 2014-07-30 EP EP14749719.2A patent/EP3027641A1/fr active Pending
- 2014-07-30 US US14/908,235 patent/US9937245B2/en active Active
- 2014-07-30 CN CN201480043265.8A patent/CN105658662B/zh active Active
- 2014-07-30 KR KR1020167004505A patent/KR102272580B1/ko active IP Right Grant
- 2014-07-30 AU AU2014298922A patent/AU2014298922B2/en active Active
-
2016
- 2016-01-11 IL IL243573A patent/IL243573B/en active IP Right Grant
- 2016-12-07 HK HK16113961A patent/HK1225744A1/zh unknown
-
2018
- 2018-01-26 US US15/881,135 patent/US10653754B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10653754B2 (en) | 2020-05-19 |
MX2016001220A (es) | 2016-05-24 |
CA2918233A1 (fr) | 2015-02-05 |
CN105658662B (zh) | 2022-05-27 |
US20180147266A1 (en) | 2018-05-31 |
KR102272580B1 (ko) | 2021-07-05 |
IL243573A0 (en) | 2016-03-31 |
KR20160036581A (ko) | 2016-04-04 |
WO2015014487A1 (fr) | 2015-02-05 |
AU2014298922A1 (en) | 2016-02-18 |
JP6517800B2 (ja) | 2019-05-22 |
EP3027641A1 (fr) | 2016-06-08 |
BR112016001730B1 (pt) | 2023-04-11 |
JP2016527257A (ja) | 2016-09-08 |
CN105658662A (zh) | 2016-06-08 |
US20160175407A1 (en) | 2016-06-23 |
RU2016103329A (ru) | 2017-08-31 |
US9937245B2 (en) | 2018-04-10 |
HK1225744A1 (zh) | 2017-09-15 |
AU2014298922B2 (en) | 2018-03-15 |
IL243573B (en) | 2019-03-31 |
RU2663136C2 (ru) | 2018-08-01 |
BR112016001730A2 (pt) | 2017-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10653754B2 (en) | Highly pure neurotoxic component of a botulinum toxin and uses thereof | |
Dahl et al. | Temperature regulates bacterial protein production: possible role in rosacea | |
Miedzobrodzki et al. | Proteolytic activity of Staphylococcus aureus strains isolated from the colonized skin of patients with acute-phase atopic dermatitis | |
Ge et al. | Conjunctival microbiome changes associated with fungal keratitis: metagenomic analysis | |
CN111050850A (zh) | 用于用表达lekti的重组微生物治疗内瑟顿综合征的组合物和方法 | |
Song et al. | Rapid identification of Pseudomonas aeruginosa from ocular isolates by PCR using exotoxin A-specific primers | |
Zhang et al. | Isolation and characterization of a trypsin inhibitor from the skin secretions of Kaloula pulchra hainana | |
US9662372B2 (en) | Compositions and methods to inactivate and/or reduce production of microbial toxins | |
Stahl et al. | Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery | |
EP3732300B1 (fr) | Nouveau milieu de culture et test de sensibilité aux antibiotiques de mycobactéries | |
Adejuwon et al. | Staphylococcus aureus isolated from septic caesaerean wound at Ile Ife Nigeria: Antibiotics susceptibility patterns | |
US10688163B2 (en) | Targeted antimicrobials and related compositions, methods and systems | |
Dhiman et al. | Clinico-microbiological profile of nontuberculous Mycobacterial Keratitis | |
Jasińska et al. | Evaluation of the role of staphylococci in the pathomechanism of conjunctivitis | |
Bharadwaz et al. | Isolation, purification, and characterization of staphylocoagulase, a blood coagulating protein from Staphylococcus sp. MBBJP S43 | |
Noble | The role of the staphylococci in dermatology | |
Saleem | Journal of Global Pharmacy Technology | |
Ali | The Influence of Streptococcus pneumoniae Serine Proteases on Pneumococcal Pathogenesis | |
RU2514662C2 (ru) | Способ определения активации плазминогена бактериями в условиях in vitro | |
Akinjogunla et al. | Heamolytic activities, deoxyribonuclease production and in-vitro flouroquinolones susceptibility profile of aerobic gram positive cocci associated with acne vulgaris. | |
Razak et al. | Molecular study of storase enzyme and characterization of some virulence factors in Streptococcus pyogenes | |
McNiven | The nature of staphylococcal α-toxin | |
NICAsl et al. | Toxins and Virulence Factors of Pseudomonas | |
Al-Akaidi | Effect of anti-lysozyme and IgA antibodies of tear film on microorganisms causing eye corneal infection | |
Abdul Rafi et al. | Identification and characterization of Xanthomonas oryzae pv oryzae in north-west of Pakistan. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20190514 |
|
EEER | Examination request |
Effective date: 20190514 |
|
EEER | Examination request |
Effective date: 20190514 |